Moreover, it is noteworthy that EGFR mutations are key drivers of NSCLC in Asian populations, making EGFR a critical target for genotype-driven therapy in this context (Melosky et al., 2021). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.